

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Guideline scope

Post-traumatic stress disorder: management

This guideline will update the NICE guideline on post-traumatic stress disorder: management (CG26) as set out in the [surveillance review decision](#).

The guideline will be developed using the methods and processes outlined in [Developing NICE guidelines: the manual](#).

For more information about why this guideline is being developed, and how the guideline will fit into current practice, see the [context](#) section.

Who the guideline is for

- People with post-traumatic stress disorder (PTSD) (including complex PTSD) and those at risk of PTSD, their families and carers and the public.
- Professionals involved in recognising PTSD and in caring for people with PTSD. These include the following professionals: GPs, psychiatrists, clinical psychologists, mental health nurses, community psychiatric nurses, social workers, practice nurses, first responders who respond to an emergency, occupational therapists, other physicians, midwives, health visitors and psychological therapists.
- Professionals in non-health sectors who are involved in providing services for people at risk of or who have PTSD. These may include professionals who work in the criminal justice and education sectors and in non-government organisations.
- People with responsibility for planning services for people with a diagnosis of PTSD and their families and carers. These include directors of public health, NHS trust managers and managers in clinical commissioning groups.

28 NICE guidelines cover health and care in England. Decisions on how they
29 apply in other UK countries are made by ministers in the [Welsh Government](#),
30 [Scottish Government](#), and [Northern Ireland Executive](#).

31 ***Equality considerations***

32 NICE has carried out [an equality impact assessment](#) [add hyperlink in final
33 version] during scoping. The assessment:

- 34 • lists equality issues identified, and how they have been addressed
- 35 • explains why any groups are excluded from the scope.

36 The guideline will look at inequalities relating to gender, sexual orientation,
37 family origin, age, homelessness, refugees and asylum seekers, people with
38 neurodevelopmental disorders, and people with comorbidities. The guideline
39 committee will be sensitive to the different approaches to PTSD in people of
40 different family origins and cultures, and be aware of the issues of both
41 internal and external social exclusion.

42 **1 What the guideline is about**

43 **1.1 Who is the focus?**

44 **Groups that will be covered**

- 45 • Adults, children and young people at risk of or with PTSD (including
46 complex PTSD).
- 47 • Family members and carers of people with PTSD: the guideline will
48 recognise their role in treating and supporting people with PTSD.
- 49 • Adults, children and young people with PTSD who have coexisting
50 conditions, such as drug and alcohol misuse, common mental health
51 disorders or personality disorders.

52 **1.2 Settings**

53 **Settings that will be covered**

- 54 • All NHS and social care commissioned services where care is provided for
55 people at risk of or with a diagnosis of PTSD.

56 **Settings that will not be covered**

- 57 • Theatres of military conflict.

58 **1.3 Activities, services or aspects of care**

59 We will look at evidence on the areas listed below when developing the
60 guideline, but it may not be possible to make recommendations on all the
61 areas.

62 **Key areas that will be covered**

63 ***Areas from the published guideline that will be updated***

- 64 1 Psychological and psychosocial interventions
- 65 2 Pharmacological interventions. Note the guideline recommendations will
66 normally fall within licensed indications; exceptionally, and only if clearly
67 supported by evidence, use outside a licensed indication may be
68 recommended. The guideline will assume that prescribers will use a
69 medicine's summary of product characteristics to inform decisions made
70 with individual patients.
- 71 3 Principles of care for all people with PTSD
- 72 4 Support for families and carers
- 73 5 Practical and social support
- 74 6 Care for people with coexisting conditions
- 75 7 Prevention

76 ***Areas from the published guideline that will not be updated***

- 77 1 Recognition
- 78 2 Assessment
- 79 3 Language and culture
- 80 4 Disaster planning

81 Recommendations in areas that are not being updated may be edited to
82 ensure that they meet current editorial standards, and reflect the current policy
83 and practice context.

84 **1.4 Economic aspects**

85 We will take economic aspects into account when making recommendations.
86 We will develop an economic plan that states for each review question (or key
87 area in the scope) whether economic considerations are relevant, and if so
88 whether this is an area that should be prioritised for economic modelling and
89 analysis. We will review the economic evidence and carry out economic
90 analyses, using an NHS and personal social services (PSS) perspective,
91 although economic analyses will attempt to incorporate wider costs associated
92 with the care of people with PTSD in other settings (for example, schools,
93 immigrant and refugee centres, and the criminal justice system) if appropriate
94 cost data are identified.

95 **1.5 Key issues and draft review questions**

96 While writing this scope, we have identified the following key issues, and key
97 questions related to them:

- 98 1 Psychological and psychosocial interventions
 - 99 1.1 For children and young people within 3 months of a traumatic event,
100 do specific psychological or psychosocial interventions, when compared
101 with other psychological or psychosocial interventions, intervention as
102 usual, waiting list or no intervention, result in a clinically important
103 reduction in symptoms or prevention of PTSD, improved functioning,
104 improved quality of life and/or adverse effects?
 - 105 1.2 For children and young people with clinically relevant post-traumatic
106 stress symptoms, do psychological or psychosocial interventions, when
107 compared with other psychological or psychosocial interventions,
108 intervention as usual, waiting list or no intervention, result in a clinically
109 important reduction of PTSD symptoms, improved functioning, improved
110 quality of life, and/or adverse effects?

111 1.3 For adults within 3 months of a traumatic event, do specific
112 psychological or psychosocial interventions, when compared with other
113 psychological and psychosocial interventions, intervention as usual,
114 waiting list or no intervention, result in a clinically important reduction of
115 PTSD symptoms or prevention of PTSD, improved functioning, improved
116 quality of life, and/or adverse effects?

117 1.4 For adults with PTSD, do specific psychological or psychosocial
118 interventions, when compared with other psychological or psychosocial
119 interventions, intervention as usual, waiting list or no intervention, result
120 in a clinically important reduction of symptoms, improved functioning,
121 improved quality of life, presence of PTSD and/or adverse effects?

122 2 Pharmacological interventions

123 2.1 For children and young people within 3 months of a traumatic event,
124 do specific pharmacological interventions, when compared with other
125 pharmacological, psychosocial or psychological interventions or placebo,
126 result in a clinically significant reduction of PTSD symptoms or
127 prevention of PTSD, improved functioning, improved quality of life,
128 and/or adverse effects?

129 2.3 For children and young people with clinically relevant post-traumatic
130 stress symptoms, do specific pharmacological interventions, when
131 compared with other pharmacological, psychological or psychosocial
132 interventions or placebo, result in a clinically important reduction of
133 PTSD symptoms or prevention of PTSD, improved functioning, improved
134 quality of life, and/or adverse effects?

135 2.2 For adults within 3 months of a traumatic event, do specific
136 pharmacological interventions, when compared with other
137 pharmacological, psychological or psychosocial interventions or placebo,
138 result in a clinically significant reduction or prevention of symptoms,
139 improved functioning, improved quality of life, presence of disorder
140 and/or adverse effects?

141 2.4 For adults with PTSD, do specific pharmacological interventions,
142 when compared with other pharmacological, psychological or
143 psychosocial interventions or placebo, result in a clinically significant

- 144 reduction of symptoms, improved functioning, improved quality of life,
145 presence of disorder and/or adverse effects?
- 146 3 Principles of care for all people with PTSD
- 147 3.1 For adults, children and young people with clinically relevant post-
148 traumatic stress symptoms, what factors should be taken into account in
149 order to provide optimal care across all conditions and coordination of
150 care?
- 151 4 Support for families and carers
- 152 4.1 What practical and social support should be made available by
153 healthcare professionals to families and carers of people with PTSD?
- 154 5 Practical support and social factors
- 155 5.1 What practical and social support should be made available by
156 healthcare professionals to help a person to recover from PTSD?
- 157 6 Care for people with coexisting conditions
- 158 6.1 For people with PTSD who present with one or more coexisting
159 conditions, should treatment for PTSD differ from treatment for those
160 without a coexisting condition, and what is the best way to address these
161 differences when delivering and coordinating care?

162 **1.6 Main outcomes**

163 The main outcomes that will be considered when searching for and assessing
164 the evidence are:

- 165 1 Symptoms of PTSD
- 166 2 Recovery from PTSD
- 167 3 Symptoms of and recovery from a coexisting condition
- 168 4 Relapse
- 169 5 Carer experience and outcomes
- 170 6 Adverse effects of treatment
- 171 7 Personal, social, educational and occupational functioning
- 172 8 Outcomes related to offending
- 173 9 Quality of life
- 174 10 Acceptability of the intervention

175 **2 Links with other NICE guidance, NICE quality** 176 **standards, and NICE Pathways**

177 **2.1 NICE guidance**

178 **NICE guidance that will be updated by this guideline**

- 179 • Post-traumatic stress disorder: management (2005) [NICE guideline CG26](#)

180 **NICE guidance about the experience of people using NHS services**

181 NICE has produced the following guidance on the experience of people using
182 the NHS. This guideline will not include additional recommendations on these
183 topics unless there are specific issues related to post-traumatic stress
184 disorder:

- 185 • [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- 186 • [Service user experience in adult mental health](#) (2011) NICE guideline
187 CG136
- 188 • [Medicines adherence](#) (2009) NICE guideline CG76

189 **NICE guidance that is closely related to this guideline**

190 ***Published***

191 NICE has published the following guidance that is closely related to this
192 guideline:

- 193 • [Antenatal and postnatal mental health: clinical management service](#)
194 [guidance](#) (2015) NICE guideline CG192
- 195 • [Children's attachment: attachment in children and young people who are](#)
196 [adopted from care, in care or at high risk of going into care](#) (2015) NICE
197 guideline NG26
- 198 • [Looked-after children and young people](#) (2015) NICE guideline PH28
- 199 • [Domestic violence and abuse: multi-agency working](#) (2014) NICE guideline
200 PH50
- 201 • [Antisocial behaviour and conduct disorders in children and young people:](#)
202 [recognition and management](#) (2013) NICE guideline CG158

- 203 • [Antisocial personality disorder: prevention and management](#) (2013) NICE
204 guideline CG77
- 205 • [Common mental health problems: identification and pathways to care](#)
206 (2011) NICE guideline CG123
- 207 • [Rehabilitation after critical illness in adults](#) (2009) NICE guideline CG83
- 208 • [Substance misuse interventions for vulnerable under 25s](#) (2007) NICE
209 guidance PH4

210 ***In development***

211 NICE is currently developing the following guidance that is closely related to
212 this guideline:

- 213 • [Child abuse and neglect](#) NICE guideline. Publication expected September
214 2017
- 215 • [Mental health of adults in contact with the criminal justice system](#) NICE
216 guideline. Publication expected February 2017
- 217 • [Severe mental illness and substance misuse \(dual diagnosis\) - community](#)
218 [health and social care services](#) NICE guideline. Publication expected
219 November 2016.

220 **2.2 NICE quality standards**

221 **NICE quality standards that may need to be revised or updated when**
222 **this guideline is published**

- 223 • Anxiety disorders (2014) NICE quality standard QS53

224 **2.3 NICE Pathways**

225 NICE Pathways bring together all related NICE guidance and associated
226 products on a topic in an interactive topic-based flow chart.


227 There is a live pathway for post-traumatic stress disorder:

228 <http://pathways.nice.org.uk/pathways/post-traumatic-stress-disorder>

229 When the revised guideline is published, the recommendations will be
230 incorporated into a revised pathway. An outline, based on the scope, is

231 included below. It will be adapted and more detail added as the
 232 recommendations are written during guideline development.

Post-traumatic stress disorder



233

234 3 Context

235 3.1 Key facts and figures

236 Post-traumatic stress disorder (PTSD) develops after a stressful event or
 237 situation of an exceptionally threatening or catastrophic nature, which is likely
 238 to cause pervasive distress in almost anyone. PTSD can affect people of all
 239 ages, including children and young people. The estimated population
 240 prevalence in adults in the UK is 2.6% in men and 3.3% in women. Around
 241 25–30% of people experiencing a traumatic event are thought to go on to
 242 develop PTSD. Some groups of people are at an increased risk, for example
 243 first responders, military personnel, refugees and people who have
 244 experienced interpersonal violence or sexual assault.

245 It is recognised that symptoms of PTSD are significantly under-reported, and
246 that many people who experience clinically significant symptoms will not seek
247 support. PTSD symptoms commonly occur alongside anxiety, depression and
248 substance misuse problems. In this context PTSD symptoms are often
249 overlooked, and remain untreated, in people who do access mental health
250 services. Symptoms can be chronic, associated with significant impairment of
251 adaptive functioning and have a negative impact upon interpersonal
252 relationships. In children and young people symptoms such as sleeping
253 difficulties may be reported rather than the symptoms of re-experiencing or
254 avoidance commonly reported by adults. It is therefore difficult to accurately
255 estimate the burden of disease.

256 **3.2 Current practice**

257 The care pathway has changed significantly since the original NICE guideline
258 on PTSD (CG26) was published in 2005. Care for adults is now provided
259 primarily through the 209 IAPT (improving access to psychological therapies)
260 services in the UK; people with PTSD comprised 1.2% of IAPT referrals in
261 2014–15. Care for children and young people with identified PTSD is provided
262 through Tier 3 or specialist CAMHS (child and adolescent mental health
263 services). Children and young people with symptoms such as sleep difficulties
264 that may in fact be undiagnosed PTSD will typically be treated within Tier 2
265 CAMHS.

266 Access to services is a significant concern for people with PTSD, as there are
267 currently long waiting times across England for psychological interventions. In
268 2014–15, 38.1% of people referred to IAPT with identified PTSD waited more
269 than 28 days for their first appointment.

270 Trauma-focused cognitive behavioural therapy (CBT) and EMDR (eye
271 movement desensitisation and reprocessing) therapy are the most common
272 treatments for PTSD symptoms in adults. Trauma-focused CBT is
273 recommended for children and young people in the current NICE guideline,
274 and is widely used. In some services play therapy is also used for younger
275 children, although this is not currently recommended by NICE.

276 The current NICE guideline recommends the use of psychological
277 interventions before pharmacological interventions. There are concerns that
278 people may not receive a sufficient 'dose' of the chosen psychological
279 intervention. For example, an audit in 2009 found that only 11% of GPs
280 reported that their patients with PTSD were receiving the recommended 8–12
281 sessions of trauma-focused CBT or EMDR therapy. Additionally, the current
282 guideline recommends treating substance misuse problems before addressing
283 PTSD symptoms, but information gathered as part of the guideline
284 surveillance review reported that parallel treatment models have now been
285 developed.

286 **3.3 Policy, legislation, regulation and commissioning**

287 **Legislation, regulation and guidance**

288 The updated PTSD guideline will provide up to date recommendations on the
289 management and treatment of PTSD. It may help inform important changes
290 to relevant legislation, regulatory frameworks and statutory or professional
291 guidance from professional bodies relating to caring for people with PTSD,
292 including The Mental Health Act 1983 and The Mental Capacity Act
293 2005. The PTSD guideline is particularly relevant to the Children's Act 1989,
294 since PTSD in children is often underdiagnosed and if PTSD has resulted
295 from neglect or maltreatment in the home and they need care by the state.
296 The PTSD guideline will address the care of high risk groups such as
297 refugees and those in the military, thus our findings will add value to the
298 Human Rights Act 1998 and The Armed Forces Covenant, respectively.

299 Commissioning PTSD services for the adult population and CAMHS services
300 for children and young people are commissioned primarily by clinical
301 commissioning groups (CCGs). In some areas funding for Tier 2 CAMHS
302 services is provided through a joint arrangement between the local authority
303 and the NHS. For people with treatment-resistant PTSD or complex
304 presentations there are also national specialist services commissioned by
305 NHS England, for example at the Maudsley Hospital in south London. Service
306 provision for co-occurring substance misuse problems varies. In some areas

307 this is commissioned and provided within the same service, but this is not
308 always the case.

309 Most community mental health services for veterans (veteran mental health
310 services) are commissioned centrally by the Department of Health. They are
311 provided by NHS trusts organised into local networks, who work
312 collaboratively with providers such as Combat Stress and the Royal British
313 Legion in some cases. The Veterans and Reserves Mental Health programme
314 is commissioned by the Ministry of Defence but is provided in collaboration
315 with the NHS.

316 Specialist inpatient mental health services for serving military personnel are
317 commissioned by the Ministry of Defence and provided by 8 NHS trusts. The
318 main costs for treatment within this group are for psychological interventions
319 and for people with complex or treatment-resistant presentations who need
320 more intensive care.

321 **4 Further information**

This is the draft scope for consultation with registered stakeholders. The consultation dates are 7 June to 5 July 2016.

The guideline is expected to be published in August 2018.

You can follow progress of the [guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

322